Novo Nordisk A/S vs Tencent Music Entertainment Group - ADR — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Tencent Music Entertainment Group - ADR trades at $8.38 (market cap $12.83B). The key difference: Novo Nordisk A/S is far larger — about 12.9× Tencent Music Entertainment Group - ADR's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Tencent Music Entertainment Group - ADR for 67 Days on average.
| NVO | TME | |
|---|---|---|
Market Cap | $165.31B | $12.83B |
Volume | 11,432,838 | 3,618,478 |
Sector | Health | Media |
52-Week High | $63.98 | $23.71 |
52-Week Low | $35.29 | $7.74 |
Typical Hold Time | 116 Days | 67 Days |
Enterprise Value | $179.56B | $10.77B |
Dividend Yield | 4.71% | 3.02% |
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Tencent Music Entertainment (TME) trades at $7.96, down 0.38% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust revenue growth to $32.9B in 2025 and net income of $11.06B, with improving profit margins. Recent developments include a $1B notes offering and a $400M share repurchase program, reflecting financial discipline. Analyst consensus is mixed with 41.7% buy ratings but a $12.50 price target suggesting significant upside from current levels.
TME presents a compelling value opportunity with attractive valuation multiples (P/E 9.33, P/S 2.46) and strong profitability metrics. However, investors face risks from intense competition, regulatory oversight in China, and recent earnings misses. The stock's current discount to analyst targets offers potential upside, but requires monitoring of user growth trends and competitive pressures from short-form video platforms.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →